Ascendis Pharma A/s (ASND)

$123.19

-1.4

(-1.12%)

Market is closed - opens 7 PM, 20 Jun 2024

Performance

  • $123.19
    $125.60
    $123.19
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.91%

    Upside

    1.91%

    downward going graph
  • $85.08
    $161.00
    $123.19
    downward going graph

    30.94%

    Downside

    52 Weeks Volatility :47.16%

    Upside

    23.48%

    downward going graph

Returns

PeriodAscendis Pharma A/s
3 Months
-15.26%
6 Months
-0.03%
1 Year
32.86%
3 Years
-12.58%

Highlights

Market Capitalization
7.2B
Book Value
- $4.15
Earnings Per Share (EPS)
-9.59
Wall Street Target Price
180.47
Profit Margin
-152.44%
Operating Margin TTM
-51.25%
Return On Assets TTM
-25.51%
Return On Equity TTM
-818.43%
Revenue TTM
329.0M
Revenue Per Share TTM
5.83
Quarterly Revenue Growth YOY
185.5%
Gross Profit TTM
39.0M
EBITDA
-354.5M
Diluted Eps TTM
-9.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.05
EPS Estimate Next Year
-0.05
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Ascendis Pharma A/s(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 46.5%

Current $123.19
Target $180.47

Company Financials

FY18Y/Y Change
Revenue
12.1M
↑ 591.57%
Net Income
-148.8M
↑ 5.0%
Net Profit Margin
-1.2K%
↑ 6868.31%
FY19Y/Y Change
Revenue
15.0M
↑ 26.41%
Net Income
-244.2M
↑ 67.58%
Net Profit Margin
-1.6K%
↓ 400.5%
FY20Y/Y Change
Revenue
8.6M
↓ 48.01%
Net Income
-515.3M
↑ 92.17%
Net Profit Margin
-6.0K%
↓ 4395.5%
FY21Y/Y Change
Revenue
8.8M
↑ 11.87%
Net Income
-434.4M
↓ 8.44%
Net Profit Margin
-4.9K%
↑ 1093.97%
FY22Y/Y Change
Revenue
54.8M
↑ 557.93%
Net Income
-624.7M
↑ 52.04%
Net Profit Margin
-1.1K%
↑ 3791.93%
FY23Y/Y Change
Revenue
266.7M
↑ 421.2%
Net Income
-481.4M
↓ 17.45%
Net Profit Margin
-180.51%
↑ 959.12%
Q4 FY22Q/Q Change
Revenue
24.5M
↑ 49.74%
Net Income
-222.2M
↑ 22.77%
Net Profit Margin
-905.91%
↑ 199.09%
Q1 FY23Q/Q Change
Revenue
36.6M
↑ 46.7%
Net Income
-121.0M
↓ 46.53%
Net Profit Margin
-330.21%
↑ 575.7%
Q2 FY23Q/Q Change
Revenue
51.7M
↑ 41.1%
Net Income
-132.5M
↑ 9.48%
Net Profit Margin
-256.23%
↑ 73.98%
Q3 FY23Q/Q Change
Revenue
48.0M
↑ 1.35%
Net Income
-162.2M
↑ 33.59%
Net Profit Margin
-337.73%
↓ 81.5%
Q4 FY23Q/Q Change
Revenue
137.7M
↑ 186.68%
Net Income
-86.9M
↓ 46.45%
Net Profit Margin
-63.09%
↑ 274.64%
Q1 FY24Q/Q Change
Revenue
103.5M
↓ 30.36%
Net Income
-141.5M
↑ 50.83%
Net Profit Margin
-136.65%
↓ 73.56%
FY18Y/Y Change
Total Assets
364.9M
↑ 51.18%
Total Liabilities
44.5M
↑ 63.74%
FY19Y/Y Change
Total Assets
758.1M
↑ 112.16%
Total Liabilities
89.2M
↑ 104.58%
FY20Y/Y Change
Total Assets
1.2B
↑ 44.78%
Total Liabilities
173.5M
↑ 77.2%
FY21Y/Y Change
Total Assets
1.2B
↑ 10.73%
Total Liabilities
228.0M
↑ 42.67%
FY22Y/Y Change
Total Assets
1.2B
↑ 0.44%
Total Liabilities
885.3M
↑ 310.56%
FY23Y/Y Change
Total Assets
825.6M
↓ 24.24%
Total Liabilities
971.3M
↑ 17.53%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 14.42%
Total Liabilities
885.3M
↑ 0.55%
Q1 FY23Q/Q Change
Total Assets
1.1B
↓ 11.33%
Total Liabilities
871.4M
↓ 3.31%
Q2 FY23Q/Q Change
Total Assets
898.9M
↓ 14.74%
Total Liabilities
828.1M
↓ 5.02%
Q3 FY23Q/Q Change
Total Assets
873.2M
↑ 6.0%
Total Liabilities
946.6M
↑ 24.73%
Q4 FY23Q/Q Change
Total Assets
825.6M
↓ 5.45%
Total Liabilities
971.3M
↑ 2.6%
Q1 FY24Q/Q Change
Total Assets
866.4M
↓ 2.8%
Total Liabilities
1.1B
↑ 7.15%
FY18Y/Y Change
Operating Cash Flow
-158.8M
↑ 45.96%
Investing Cash Flow
-3.0M
↑ 181.4%
Financing Cash Flow
232.5M
↑ 62.98%
FY19Y/Y Change
Operating Cash Flow
-197.1M
↑ 26.75%
Investing Cash Flow
-5.8M
↑ 94.83%
Financing Cash Flow
552.9M
↑ 142.83%
FY20Y/Y Change
Operating Cash Flow
-334.0M
↑ 54.34%
Investing Cash Flow
-358.2M
↑ 5544.49%
Financing Cash Flow
741.3M
↑ 22.09%
FY21Y/Y Change
Operating Cash Flow
-473.0M
↑ 53.8%
Investing Cash Flow
-125.2M
↓ 62.03%
Financing Cash Flow
397.9M
↓ 41.69%
FY22Y/Y Change
Operating Cash Flow
-531.0M
↑ 18.69%
Investing Cash Flow
66.1M
↓ 155.83%
Financing Cash Flow
425.0M
↑ 12.92%
Q4 FY22Q/Q Change
Operating Cash Flow
-151.8M
↑ 43.36%
Investing Cash Flow
-853.8K
↓ 105.65%
Financing Cash Flow
1.4M
↓ 1875.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-160.4M
↑ 3.78%
Investing Cash Flow
51.2M
↓ 5991.72%
Financing Cash Flow
-765.5K
↓ 152.04%
Q2 FY23Q/Q Change
Operating Cash Flow
-167.1M
↑ 4.14%
Investing Cash Flow
51.2M
↑ 0.0%
Financing Cash Flow
-2.5M
↑ 228.92%
Q3 FY23Q/Q Change
Operating Cash Flow
-124.7M
↓ 18.55%
Investing Cash Flow
22.2M
↓ 52.68%
Financing Cash Flow
143.4M
↓ 6308.66%

Technicals Summary

Sell

Neutral

Buy

Ascendis Pharma A/s is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • RA Capital Management, LLC

    17.70%
  • Artisan Partners Limited Partnership

    9.93%
  • FMR Inc

    8.65%
  • Westfield Capital Management Company, LP

    7.14%
  • venBio Select Advisor LLC

    6.95%
  • HHG PLC

    6.60%

Corporate Announcements

  • Ascendis Pharma A/s Earnings

    Ascendis Pharma A/s’s price-to-earnings ratio stands at None

    Read More

Company Information

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.

Organization
Ascendis Pharma A/s
Employees
879
CEO
Mr. Jan Moller Mikkelsen
Industry
Health Technology

FAQs